COPENHAGEN, Denmark,
Nov. 23, 2021 /PRNewswire/ --
Vipergen, a leading provider of small-molecule drug discovery
services based on DNA-encoded library (DEL) technologies, announced
today the signing of a multi-target drug discovery agreement with
Aligos Therapeutics, Inc. (Nasdaq: ALGS). Under the terms of the
agreement, Vipergen will apply its high-fidelity DEL technology
platforms to identify novel small-molecule compounds that bind to
selected Aligos protein targets. Aligos will select hits for
development into novel therapeutics for viral and liver diseases.
Aligos will retain exclusive rights to globally commercialize any
products resulting from the collaboration. Financial details of the
agreement were not disclosed.
"We are delighted to collaborate with Aligos' highly experienced
team in its mission to develop best-in-class therapies that improve
treatment outcomes in chronic hepatitis B, NASH, and coronavirus,"
said Nils Hansen, PhD, Chief
Executive Officer of Vipergen. "We look forward to applying our
suite of DEL technologies to discover novel leads that help expand
Aligos' portfolio of differentiated drug candidates that target
these significant unmet medical needs."
About Vipergen ApS
Vipergen is a world-leading
provider of small-molecule drug discovery services based on
DNA-encoded library (DEL) technologies and is the first and only
company capable of screening DELs inside a living cell. Vipergen
provides its proprietary suite of leading-edge DEL technologies
through funded discovery partnerships with leading pharmaceutical
and biotechnology companies, including top pharmaceutical companies
in the U.S., EU, and Japan. For
more details about Vipergen and the YoctoReactor® (yR), Binder Trap
Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug
discovery technology platforms, please visit www.vipergen.com.
Contact:
Mary
Moynihan
M2Friend Biocommunications
+1 (802) 951-9600
mary@m2friend.com
View original
content:https://www.prnewswire.com/news-releases/vipergen-establishes-research-partnership-with-aligos-therapeutics-focused-on-dna-encoded-library-del-based-drug-discovery-for-viral-infections-and-liver-diseases-301430371.html
SOURCE Vipergen